500 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by RPg Family Wealth Advisory LLC

RPg Family Wealth Advisory LLC acquired a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 500 shares of the medical research company’s stock, valued at approximately $34,000.

Other institutional investors have also made changes to their positions in the company. William Blair Investment Management LLC acquired a new stake in Exact Sciences during the 2nd quarter valued at approximately $163,896,000. Sculptor Capital LP acquired a new stake in shares of Exact Sciences during the second quarter worth approximately $32,819,000. Samlyn Capital LLC acquired a new stake in shares of Exact Sciences during the second quarter worth approximately $30,426,000. Armistice Capital LLC increased its stake in shares of Exact Sciences by 91.6% in the second quarter. Armistice Capital LLC now owns 1,400,086 shares of the medical research company’s stock worth $59,154,000 after buying an additional 669,438 shares during the last quarter. Finally, Champlain Investment Partners LLC boosted its stake in Exact Sciences by 10.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock valued at $169,924,000 after acquiring an additional 245,980 shares during the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

Exact Sciences stock opened at $61.69 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The company has a market cap of $11.42 billion, a P/E ratio of -52.73 and a beta of 1.27. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The firm’s 50 day simple moving average is $64.35 and its 200-day simple moving average is $55.89.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. Exact Sciences’s quarterly revenue was up 12.8% on a year-over-year basis. As a group, equities research analysts predict that Exact Sciences Co. will post -1.13 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. TD Cowen lifted their target price on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday. Stifel Nicolaus lowered their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Robert W. Baird reduced their price target on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Citigroup dropped their price objective on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company assumed coverage on Exact Sciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $75.00 target price on the stock. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.29.

Insider Activity

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at $893,060. This represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin T. Conroy purchased 19,500 shares of Exact Sciences stock in a transaction on Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the transaction, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.36% of the stock is owned by corporate insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.